PSI

PSI is the leading pivotal-stage radiopharmaceutical CRO, running over 40% of the industry’s registrational nuclear medicine trials.

We specialize in delivering complex global diagnostic and theragnostic trials. Our strength lies in coordinating multidisciplinary site teams, ensuring regulatory and logistical readiness, providing specialized site support, and developing tailored recruitment strategies for radiopharmaceutical research.

In 2025, PSI is celebrating its 30th year as the only fully independent and privately owned mid-sized CRO. For more information, visit www.psi-cro.com.